Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 4/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 9/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.40 |
| ▸ | ESRRA | P11474 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876001 | 1.00 | AR (0.42) | ARSLC22A12SCN9AESRRA | |
| SCHEMBL876002 | 1.00 | AR (0.42) | ARSLC22A12SCN9AESRRA | |
| SCHEMBL876120 | 0.87 | AR (0.41) | ARSLC22A12ESRRA | |
| SCHEMBL876119 | 0.87 | AR (0.41) | ARSLC22A12ESRRA | |
| SCHEMBL876302 | 0.84 | SLC22A12 (0.42) | ARSLC22A12SCN9A | |
| SCHEMBL875698 | 0.84 | SCN9A (0.44) | ARSLC22A12SCN9A | |
| SCHEMBL15832080 | 0.83 | SLC22A12 (0.49) | ARSLC22A12 | |
| SCHEMBL876360 | 0.78 | ESRRA (0.43) | ARSCN9AESRRA | |
| SCHEMBL876526 | 0.78 | ESRRA (0.43) | ARSCN9AESRRA | |
| SCHEMBL876361 | 0.78 | ESRRA (0.43) | ARSCN9AESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | AR 3517/4885SLC22A12 2850/4885SCN9A 4613/4885 |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | AR 3517/4885SLC22A12 2850/4885SCN9A 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.